标题
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 3, Pages 429-435
出版商
Informa Healthcare
发表日期
2012-12-17
DOI
10.1517/14712598.2012.748743
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
- (2012) Hua Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
- (2012) Ekaterina Chernogubova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
- (2012) Payal Kohli et al. CLINICAL CARDIOLOGY
- Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
- (2012) Javier Chaparro-Riggers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY
- (2012) Clapton Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
- (2012) Roeland Huijgen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia
- (2011) Michel Farnier American Journal of Cardiovascular Drugs
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients
- (2011) Edward J. Mills et al. EUROPEAN HEART JOURNAL
- PCSK9: an emerging target for treatment of hypercholesterolemia
- (2011) Christopher J Duff et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
- (2011) Brandon Ason et al. JOURNAL OF LIPID RESEARCH
- Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
- (2011) Robert J Konrad et al. Lipids in Health and Disease
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition
- (2011) G. Tibolla et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
- (2008) Edward J. Mills et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Abetalipoproteinemia: two case reports and literature review
- (2008) Rola Zamel et al. Orphanet Journal of Rare Diseases
- Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
- (2007) Vivienne M. Homer et al. ATHEROSCLEROSIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started